Opinion|Videos|September 24, 2024
Patient Feedback for MDS: Insights and Closing Remarks
Medical experts offer their insights and closing remarks regarding patient feedback for MDS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you address challenges related to medication adherence in patients with myelodysplastic syndromes (MDS) receiving oral decitabine-cedazuridine, and what strategies or tips have you found effective in promoting adherence to treatment regimens?
- How can we leverage patient feedback and experiences to continuously improve MDS treatment strategies and enhance patient outcomes?
Advertisement
Related to this article
In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
SURPASS-CVOT data show fewer deaths or HF events with tirzepatide vs dulaglutide in patients with HF, driven largely by mortality.
Subcutaneous mosunetuzumab plus polatuzumab vedotin boosts responses in relapsed large B-cell lymphoma, helping community oncology care.
Using baseline samples from 177 patients in the VISION/HO141 trial, researchers built a functional prognostic model for CLL that outperformed the CLL-IPI.
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
3
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
4
Admilparant Phase 3 ALOFT-IPF Trial Meets Primary End Point in IPF
5